NEW YORK – Repare Therapeutics on Tuesday said it will regain rights to camonsertib after its collaboration agreement with Roche to develop the ATR inhibitor ended.
Roche, after reviewing its pipeline and external factors last year, terminated its worldwide license and collaboration agreement with Repare for the development and commercialization of camonsertib. The two companies entered into the deal in June 2022, which was worth up to $1.2 billion in milestone payments and royalties. Repare will now regain full rights to the agent.
Roche was developing camonsertib as a treatment for tumors with synthetic-lethal genomic alterations. There are several ongoing studies of the drug, including a Phase I/II combination study with Pfizer's PARP inhibitor Talzenna (talazoparib) or chemo in patients with solid tumors with ATR inhibitor-sensitizing mutations. Repare was also studying the drug in combination with its PKMYT1 inhibitor lunresertib in patients with molecularly informed, advanced solid tumors.
The firm was studying camonsertib in combination with PARP inhibitors, either GlaxoSmithKline's Zejula (niraparib) or AstraZeneca's Lynparza (olaparib), in patients with solid tumors. Camonsertib was also included in an arm of the TAPISTRY platform trial, involving patients with ATM loss-of-function tumors and SETD2 loss-of-function tumors.
"Camonsertib is a valuable, high-potential precision oncology medicine that has achieved clinical proof of concept in multiple tumor types and genotypes both as monotherapy and in combination, as previously reported," Repare CEO Lloyd Segal said in a statement. "We have been continuously running clinical trials for camonsertib since July 2020 and are excited to steward the progress of this promising therapy. While we are disappointed to end this collaboration, we appreciate the contributions Roche has made to the program."
Repare, based in Cambridge, Massachusetts, is also developing a PLK4 inhibitor RP-1664 in TRIM37-high cancers and a pol theta inhibitor RP-3467 in BRCA1/2-mutant tumors, which the company said were expected to enter clinical studies this year. The company discovers and develops precision oncology products using the CRISPR-based SNIPRx screening platform, which uses proprietary isogenic cell lines to home in on synthetic lethal gene pairs and identify patients whose tumors have corresponding genetic profiles that make them likely to respond to therapies it is developing.